



Ifw

Docket No.: SC65U-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Michelle D. Hines, et al.		
Serial No.	10/738,412	Group Art Unit:	1617
Filed	December 17, 2003	Examiner:	Not Yet Assigned
For	THIAZOLE DERIVATIVES		

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is:

1. Transmittal Letter (1 page);
2. Information Disclosure Statement (1 page);
3. Search Report/Communication cited in a corresponding PCT or foreign counterpart application (4 pages);
4. Information Disclosure Statement (2 pages and copy of references) and
5. Return postcard.

Please charge any additional fees or credits any such fees, if necessary to Deposit Account No. 01-3040 in the name of Avon Products, Inc. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: 9/29/2005

Charles J. Zeller, Esq.
Reg. No. 28,682
AVON PRODUCTS, INC.
Avon Place
Suffern, New York 10901
Tel: 845-369-2113
Fax: 845-369-2900

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Kathy S. Abrams

Kathy S. Abrams
SIGNATURE

9/30/05
DATE



Docket No.: SC65U-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Michelle D. Hines, et al.
Serial No. : 10/738,412 Group Art Unit: 1617
Filed : December 17, 2003 Examiner: Not Yet Assigned
For : THIAZOLE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313 1450

Dear Sir:

In accordance with applicants' duty of disclosure under 37 C.F.R. §1.56, we are enclosing Form SB/08A listing information that may be material to the patentability of this application.

It should be understood that attention has been called to the references that have been deemed to be pertinent to the claimed present invention. In concluding what was pertinent, the criteria employed was considered most appropriate in light of the invention shown in the present application. However, the Examiner or others may deem some other criteria to be just as appropriate or more appropriate. Therefore, the Examiner is respectfully urged to review the listed references and to make the usual careful independent search for other prior art that may be pertinent.

Applicants respectfully request favorable consideration and this application be passed to allowance.

Respectfully submitted,

Date: 9/29/2003

Charles J. Zeller, Esq.
Reg. No. 28,682
AVON PRODUCTS, INC.
Avon Place
Suffern, New York 10901
Tel: 845-369-2113
Fax: 845-369-2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	10/738,412
Filing Date	December 17, 2003
First Named Inventor	Hines et al.
Art Unit	1617
Examiner Name	not yet assigned
Attorney Docket Number	SC65U-US

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 02/053161	07-11-2002	Alteon, Inc.		
		WO 01/62250	08-30-2001	Alteon, Inc.		
		WO 01/62247	08-30-2001	Avon Products,		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/738,412
Filing Date	December 17, 2003
First Named Inventor	Hines, et al.
Art Unit	1617
Examiner Name	not yet assigned
Attorney Docket Number	SC65U-US

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DEGROOT, JEROEN; The AGE of the matrix: chemistry, consequence and cure; Current Opinion in Pharmacology 2004, 4:3001-3005.	
		BROWNLEE M. Advanced protein glycosylation in diabetes and aging; Ann. Rev. Med. 1995, 46:223-34.	
		BROWNLEE M., CERAMI A. VLASSARA H.A.; Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications; N. Engl. J. Med. 1988, 318, 1315-1321.	
		BROWNLEE M., VLASSARA H., KOONEY A., ULRICH P., CERAMI A., Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science; 1986, 232: 1629-1632.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.